Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05109507 · ClinicalTrials.gov registry record · NA

Single-Session Intervention Targeting Emotional Awareness, Clarity, and Acceptance to Reduce Depression/Anxiety

A NA study, sponsored by Yale University.

Completed
Registry status
NA
Development phase
530
Enrollment target

NCT05109507: Completed NA study, sponsored by Yale University.

NCT05109507 is a NA study that has completed, run by Yale University. The registered enrollment target is 530 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05109507, a NA study, has completed, sponsored by Yale University.

COMPLETED
Registry status
NA
Development phase
530 participants
Enrollment target

Study Summary

Two-arm, parallel group randomized clinical trial conducted via Mturk comparing a single-session web-based intervention called Visitor Mindset versus a control intervention (nature videos with relaxing music) for adults with depression and/or anxiety symptoms

Primary Outcome

Patient Health Questionnaire-Anxiety Depression Scale (PHQ-ADS). Total scores range from 0 to 27, with higher scores indicating greater anxiety/depression symptoms.

Interventions

  • BEHAVIORAL Relaxing with Nature
  • BEHAVIORAL Visitor Mindset

Trial Details

FieldValue
Enrollment Target 530 participants
Start Date 2021-10-18
Est. Completion 2021-12-01
Phase NA
Yale University

1,492 total trials

What the finished NCT05109507 record still lists

NCT05109507 is an interventional study that assigns participants to a tested intervention. The registered 530 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (62% lower).

The record links to 0 conditions, and to 2 interventions - of which Relaxing with Nature is the first listed.

NCT05109507 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05109507 about?

NCT05109507 is a clinical study titled "Single-Session Intervention Targeting Emotional Awareness, Clarity, and Acceptance to Reduce Depression/Anxiety". Two-arm, parallel group randomized clinical trial conducted via Mturk comparing a single-session web-based intervention called Visitor Mindset versus a control intervention (nature videos with relaxing music) for adults with depression and/or anxiety symptoms

What is the current status of trial NCT05109507?

This trial is currently completed. It is a NA study. The enrollment target is 530 participants. The study started on 2021-10-18. Estimated completion is 2021-12-01.

What interventions are being tested in trial NCT05109507?

The interventions under investigation include: Relaxing with Nature (BEHAVIORAL), Visitor Mindset (BEHAVIORAL).

Who is sponsoring clinical trial NCT05109507?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05109507's enrollment target sits among peer trials

530 188th of 2000 higher than 1,813 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06646276 · 530 participants · Phase 3

    A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

  • NCT06703476 · 530 participants · Phase 3

    A Study of Surgical Techniques During Cystectomy

  • NCT06880744 · 530 participants · Phase 3

    A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  • NCT07138040 · 530 participants · NA

    Re-Engaging AYA Survivors in Cancer-Related Healthcare

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05109507, the US trial registry maintained by the National Library of Medicine. NCT05109507 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.